Dalerba Lab
Piero Dalerba, M.D., is an associate member of the Center for Discovery and Innovation.
Dr. Dalerba and his team focus on the discovery of biomarkers that are predictive of tumor response to anti-neoplastic drugs, in order to improve therapeutic guidelines and decision-making algorithms for cancer patients. Dr. Dalerba's team uses single-cell technologies (e.g., FACS, single-cell RNA-sequencing) to deconvolute the cell composition of malignant tissues and identify anti-tumor drugs that have selective activity against specific subtypes of cancer cells.
Dr. Dalerba brought his research to the CDI in 2024. His prior appointments were as Assistant Professor of Pathology and Cell Biology at Columbia University, and as Instructor of Medicine at Stanford University. He earned his medical degree (MD) from the University of Milan (Italy) in 1995, and has received a series of distinctions over his career including: the 9th International PBI Valentina Lana Prize in Molecular Immunology (2002), a BD Biosciences Stem Cell Research Grant (2011), a National Comprehensive Cancer Network (NCCN) Young Investigator Award (2012), a Runyon-Rachleff Innovation Award from the Damon Runyon Cancer Research Foundation (2016), a Schaefer Research Scholarship from Columbia University (2017), a Breast Cancer Alliance (BCA) Young Investigator Grant (2018), a Kara Gelb Memorial Grant (2018) from the Adenoid Cystic Carcinoma Research Foundation (ACCRF), a VELOCITY Fellow Grant Award from the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University (2019), and a Columbia Stem Cell Initiative (CSCI) Seed Fund Award (2022), among other awards and grants."
Selected Publications
Piero Dalerba, Scott J Dylla, In-Kyung Park 2007| Phenotypic characterization of human colorectal cancer stem cells. PNAS 2007 Jun 12;104(24):10158-63.
Piero Dalerba, Tomer Kalisky, Debashis Sahoo. 2011 | Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol. 2011 Nov 13;29(12):1120-7.
Piero Dalerba, Debashis Sahoo, Soonmyung Paik 2016 | CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med.. 2016 Jan 21;374(3):211-22.
William J Raab, Arabella Mazzocchi, Paolo Radice. 2022 | A Microsatellite in the Coding Sequence of HLA-A/B Is a Mutation Hotspot in Colon Cancer With Microsatellite Instability. Gastroenterology. 2022 Mar;162(3):960-963.e3.
Sara Viragova, Luis Aparicio, Pierangela Palmerini. 2023 | Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. J Natl Cancer Inst. 2023 Jul 6;115(7):838-852.
Reviews and Editorials
The Dynamic Identity of Intestinal Cancer Stem Cells
Cancer stem cells and tumor metastasis: first steps into uncharted territory
Cancer stem cells: models and concepts
For a complete list of publications, please visit PubMed.gov